GlassScriptPhysician profile
Maureen Connolly
NPI 1073971016
$2,669.04
in general payments reported to CMS, 2019-2025
19 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $641 · 2023: $945 · 2024: $716 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $360.39 | 2023-2025 | Koselugo, Strensiq |
| Astrazeneca Pharmaceuticals LP | $243.28 | 2022-2025 | Airsupra |
| Heartflow, INC. | $145.72 | 2023 | Ffrct |
| Abbott Laboratories | $142.00 | 2022 | |
| Alnylam Pharmaceuticals INC. | $126.75 | 2025 | Amvuttra |
| Mylan Specialty L.P. | $125.00 | 2024 | Yupelri |
| Gilead Sciences, INC. | $125.00 | 2024 | Epclusa |
| Amgen INC. | $124.99 | 2024 | Repatha |
| Janssen Pharmaceuticals, INC | $124.99 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.99 | 2023 | |
| Organogenesis INC. | $124.99 | 2023 | Puraply Antimicrobial |
| Abbvie INC. | $124.58 | 2023 | |
| Esperion Therapeutics, INC. | $124.58 | 2022 | |
| Idorsia Pharmaceuticals US INC | $124.47 | 2022 | |
| Viiv Healthcare Company | $121.51 | 2024 | Dovato |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $117.19 | 2023 | Inspire |
| Shield Therapeutics INC | $107.76 | 2024 | |
| Biogen, INC. | $93.48 | 2023 | Spinraza |
| Impel Pharmaceuticals INC. | $87.37 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Connolly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.